touchEXPERT BRIEFING Advances in the treatment of CSU
Watch leading experts discuss updates in the treatment of chronic spontaneous urticaria (CSU), based on data presented at EAACI 2024.
We were deeply saddened to learn of the passing of Prof. Dr Marcus Maurer, and our hearts and deepest sympathies are with his family and close friends. We feel privileged to have worked alongside someone whose groundbreaking work has made a significant impact on dermatology and immunology.Â
The burden of CSU – what still needs to be done?
In this interview, Prof. Ana Maria Giménez-Arnau outlines how to improve understanding of the burden of CSU. She discusses the condition itself and examines how patients describe the impact of living with CSU. She also covers the impact on healthcare systems, focusing on the importance of reducing delays in diagnosis.
Prof. Giménez-Arnau emphasises the importance of swift diagnosis and control, by reviewing the current state of care for CSU, starting with second-generation anti-H1 antihistamines. She addresses dosage increases when initial treatments fail, and concludes by spotlighting the unmet need in the current treatment landscape for patients who do not achieve optimal outcomes with current treatments.
view bio and disclosures 1/6 Next InterviewIn this interview, Prof. Ana Maria Giménez-Arnau answers the following questions:
- What is chronic spontaneous urticaria (CSU)?
- What impact does the condition have on your patients?
- How does this condition affect healthcare services?
- How is CSU managed and are there any limitations of current treatments?
Prof. Ana Maria Giménez-Arnau is Associate Professor of Dermatology at the Department of Dermatology, Hospital del Mar Research Institute, Pompeu Fabra University, Barcelona, Spain.
Prof. Ana Maria Giménez-Arnau discloses:
Speaker and/or advisor for and/or has research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceuticals, Genentech, GSK, Instituto Carlos III- FEDER, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Noucor, Novartis, Sanofi Regeneron, Servier, Thermo Fisher Scientific, and Uriach Pharma.
Improving the quality of life of those living with CSU
At EAACI 2024, Prof. Ana Maria Giménez-Arnau presented key data on the impact of novel BTK inhibitors on patients’ quality of life (QoL) and daily activities. To contextualize these results, she explores the various aspects of QoL affected by CSU and discusses the crucial link between QoL and disease control, emphasising the importance of achieving complete disease control.
Prof. Giménez-Arnau concludes by touching on the wealth of new information presented at EAACI that could enhance patients’ QoL.
view bio and disclosures 2/6 Next InterviewIn this interview, Prof. Ana Maria Giménez-Arnau answers the following questions:
- How can chronic spontaneous urticaria (CSU) affect a person’s quality of life?
- In relieving clinical symptoms, how important is it to also focus on improving a patient's overall quality of life and daily functioning?
- How can patients' quality of life be addressed and improved?
- If well-controlled CSU is key to improving QoL, what new data was presented at EAACI that could help patients achieve this?
Prof. Ana Maria Giménez-Arnau is Associate Professor of Dermatology at the Department of Dermatology, Hospital del Mar Research Institute, Pompeu Fabra University, Barcelona, Spain.
Prof. Ana Maria Giménez-Arnau discloses:
Speaker and/or advisor for and/or has research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceuticals, Genentech, GSK, Instituto Carlos III- FEDER, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Noucor, Novartis, Sanofi Regeneron, Servier, Thermo Fisher Scientific, and Uriach Pharma.
Real-world challenges to effective CSU management
At EAACI 2024, Prof. Jonathan A Bernstein presented the results from the Urticaria Voices study, which looked at physicians’ prescribing patterns and perceptions of treatments for chronic spontaneous urticaria (CSU).
In this video, Prof. Bernstein explores these findings and discusses the real-world challenges and barriers that exist to practical diagnosis and management. He highlights the use and adherence to the algorithmic recommendations defined in current guidelines as a key barrier and explores why challenges like these may exist and how they could be overcome moving forward.
view bio and disclosures 3/6 Next InterviewIn this interview, Prof. Jonathan Bernstein answers the following questions:
- In your opinion, and from the results of the Urticaria Voices study, what are the greatest barriers to optimal management and treatment of CSU?
- What challenges do healthcare professionals face in integrating new management strategies and treatments into clinical practice?
- How could these barriers and challenges be overcome?
Prof. Jonathan A Bernstein is Professor of Medicine at the University of Cincinnati, Division of Rheumatology, Allergy and Immunology, Cincinnati, OH, USA.
Prof. Jonathan A Bernstein discloses:
Consulting, grant/research support, and advisory boards for Allakos, Amgen, AstraZeneca, Celldex, Escient, Genentech, Novartis, and Sanofi Regeneron. Speaker’s bureaus for AstraZeneca, Genentech, Novartis, and Sanofi Regeneron. Principal investigator (PI) and consultant for Blueprint Medicine. PI for Cogent and Telios.
Understanding and improving the patient journey
Significant delays between the initial presentation of symptoms, diagnosis and treatment exist for those living with CSU. Understanding the reasons for this and how they can be addressed is vital to improving the patient journey.
In this interview, Prof. Jonathan A Bernstein explores how to improve understanding of the reasons behind the delay and how the process from diagnosis, to treatment, to control of disease may be better streamlined. Increasing awareness, providing further education and greater access to centres of excellence are suggested measures but he also covers the potential impact that novel treatments, such as BTK inhibitors, could have on improving the patient journey.
view bio and disclosures 4/6 Next InterviewIn this interview, Prof. Jonathan Bernstein answers the following questions:
- With CSU, why is there often a substantial delay between the initial presentation of symptoms, diagnosis, and treatment?
- How could we reduce the delay between initial presentation and diagnosis?
- What other measures could be taken to streamline this process?
- Could biomarkers and novel treatments help improve this journey?
- What future directions do you see for novel treatments like BTK inhibitors in CSU management, and how could they improve the patient journey?
Prof. Jonathan A Bernstein is Professor of Medicine at the University of Cincinnati, Division of Rheumatology, Allergy and Immunology, Cincinnati, OH, USA.
Prof. Jonathan A Bernstein discloses:
Consulting, grant/research support, and advisory boards for Allakos, Amgen, AstraZeneca, Celldex, Escient, Genentech, Novartis, and Sanofi Regeneron. Speaker’s bureaus for AstraZeneca, Genentech, Novartis, and Sanofi Regeneron. Principal investigator (PI) and consultant for Blueprint Medicine. PI for Cogent and Telios.
Key data and advancements in the treatment of CSU
In this interview, Prof. Dr Marcus Maurer provided his expert insights on some of the most promising treatment data presented at EAACI 2024.
view bio and disclosures 5/6 Next InterviewIn this interview, Prof. Dr Marcus Maurer answers the following question:
- What were the key highlights in CSU presented at EAACI 2024?
Prof. Dr Marcus Maurer was Professor of Dermatology and Allergy. He was Executive Director of the Institute of Allergology at the Charité – Universitätsmedizin Berlin, Germany, as well as Co-Director of Immunology and Allergology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP.
Prof. Dr Marcus Maurer disclosed:
Speaker and/or advisor for and/or received research funding from Allakos, Alexion, Almirall, Alvotech, Amgen, Aquestive, Arcensus, argenX, AstraZeneca, Astria, BioCryst, Blueprint, Celldex, Celltrion, Clinuvel, Cogent, CSL Behring, Escient, Evoemmune, Excellergy, GSK, Incyte, Jasper, Kashiv, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Pharvaris, Resonance Medicine, Sanofi Regeneron, Santa Ana Bio, Septerna, Servier, Takeda, Teva, Third HarmonicBio, Valenza Bio, Vitalli Bio, Yuhan Corporation, and Zurabio.
BTK inhibition: A viable therapeutic approach for CSU?
In this interview, Prof. Dr Maurer explores the role of investigational BTK inhibitors in managing CSU.
He examines their impact on clinical practice, how they could be integrated into current treatment paradigms, and identifies specific patient populations that could benefit most from these advancements.
view bio and disclosures 6/6 Leave FeedbackIn this interview, Prof. Dr Marcus Maurer answers the following questions:
- Why is BTK inhibition considered a viable therapeutic approach for treating CSU?
- How do you see BTK inhibitors fitting into the future treatment landscape for CSU?
- What (if any) questions remain unanswered about this class of medication for treating this condition?
Prof. Dr Marcus Maurer was Professor of Dermatology and Allergy. He was Executive Director of the Institute of Allergology at the Charité – Universitätsmedizin Berlin, Germany, as well as Co-Director of Immunology and Allergology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP.
Prof. Dr Marcus Maurer disclosed:
Speaker and/or advisor for and/or received research funding from Allakos, Alexion, Almirall, Alvotech, Amgen, Aquestive, Arcensus, argenX, AstraZeneca, Astria, BioCryst, Blueprint, Celldex, Celltrion, Clinuvel, Cogent, CSL Behring, Escient, Evoemmune, Excellergy, GSK, Incyte, Jasper, Kashiv, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Pharvaris, Resonance Medicine, Sanofi Regeneron, Santa Ana Bio, Septerna, Servier, Takeda, Teva, Third HarmonicBio, Valenza Bio, Vitalli Bio, Yuhan Corporation, and Zurabio.
Overview & Learning Objectives
Overview
Watch three leading experts, Drs Giménez-Arnau, Bernstein and Maurer, discuss updates in the treatment of chronic spontaneous urticaria (CSU), based on data presented at EAACI 2024.
Learning Objectives
After watching this activity, participants should be better able to:
- Appreciate the burden of CSU, the current treatment landscape, and unmet medical needs
- Understand the real-world challenges in the diagnosis, treatment and management of CSU, and discuss practical insights and potential solutions
- Provide an overview of novel treatments, new approaches, and recent advances that may improve the CSU patient journey and day-to-day quality of life
Faculty & Disclosures
Prof. Ana Maria Giménez-Arnau
University Pompeu Fabra, Barcelona, Spain
Prof. Ana Maria Giménez-Arnau is Associate Professor of Dermatology at the Department of Dermatology, Hospital del Mar Research Institute, Pompeu Fabra University, Barcelona, Spain.
Prof. Ana Maria Giménez-Arnau discloses:
Speaker and/or advisor for and/or has research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceuticals, Genentech, GSK, Instituto Carlos III- FEDER, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Noucor, Novartis, Sanofi Regeneron, Servier, Thermo Fisher Scientific, and Uriach Pharma.
Prof. Jonathan A Bernstein
University of Cincinnati, Cincinnati, OH, USA
Prof. Jonathan A Bernstein is Professor of Medicine at the University of Cincinnati, Division of Rheumatology, Allergy and Immunology, Cincinnati, OH, USA.
Prof. Jonathan A Bernstein discloses:
Consulting, grant/research support, and advisory boards for Allakos, Amgen, AstraZeneca, Celldex, Escient, Genentech, Novartis, and Sanofi Regeneron. Speaker’s bureaus for AstraZeneca, Genentech, Novartis, and Sanofi Regeneron. Principal investigator (PI) and consultant for Blueprint Medicine. PI for Cogent and Telios.
Prof. Dr Marcus Maurer
Charité University Medicine; Fraunhofer Translational Medicine and Pharmacology, Berlin, Germany
Prof. Dr Marcus Maurer was Professor of Dermatology and Allergy. He was Executive Director of the Institute of Allergology at the Charité – Universitätsmedizin Berlin, Germany, as well as Co-Director of Immunology and Allergology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP.
Prof. Dr Marcus Maurer discloses:
Speaker and/or advisor for and/or received research funding from Allakos, Alexion, Almirall, Alvotech, Amgen, Aquestive, Arcensus, argenX, AstraZeneca, Astria, BioCryst, Blueprint, Celldex, Celltrion, Clinuvel, Cogent, CSL Behring, Escient, Evoemmune, Excellergy, GSK, Incyte, Jasper, Kashiv, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Pharvaris, Resonance Medicine, Sanofi Regeneron, Santa Ana Bio, Septerna, Servier, Takeda, Teva, Third HarmonicBio, Valenza Bio, Vitalli Bio, Yuhan Corporation, and Zurabio.
